185 related articles for article (PubMed ID: 8165623)
21. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
22. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Caccamo DV; Keohane ME; McKeever PE
Mod Pathol; 1994 Jan; 7(1):99-104. PubMed ID: 8159659
[TBL] [Abstract][Full Text] [Related]
24. Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy.
Coolman M; de Groot CJ; Steegers EA; Geurts-Moespot A; Thomas CM; Steegers-Theunissen RP; Sweep FC
Eur J Obstet Gynecol Reprod Biol; 2006; 128(1-2):22-8. PubMed ID: 16584829
[TBL] [Abstract][Full Text] [Related]
25. Plasminogen activators and their inhibitors in human saliva and salivary gland tissue.
Virtanen OJ; Sirén V; Multanen J; Färkkilä M; Leivo I; Vaheri A; Koskiniemi M
Eur J Oral Sci; 2006 Feb; 114(1):22-6. PubMed ID: 16460337
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activators and inhibitors are transcribed during early macaque implantation.
Feng Q; Liu K; Liu YX; Byrne S; Ockleford CD
Placenta; 2001; 22(2-3):186-99. PubMed ID: 11170823
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
28. The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer.
Herszényi L; Plebani M; Cardin R; Carraro P; De Paoli M; Roveroni G; Naccarato R; Farinati F
Acta Physiol Hung; 1995; 83(3):213-21. PubMed ID: 8852646
[TBL] [Abstract][Full Text] [Related]
29. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
Span PN; Witjes JA; Grebenchtchikov N; Geurts-Moespot A; Moonen PM; Aalders TW; Vriesema JL; Kiemeney LA; Schalken JA; Sweep FC
BJU Int; 2008 Jul; 102(2):177-82. PubMed ID: 18336603
[TBL] [Abstract][Full Text] [Related]
30. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
31. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
32. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
[TBL] [Abstract][Full Text] [Related]
33. Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen.
España F; Gilabert J; Estellés A; Romeu A; Aznar J; Cabo A
Thromb Res; 1991 Nov; 64(3):309-20. PubMed ID: 1725227
[TBL] [Abstract][Full Text] [Related]
34. Interaction of plasma kallikrein with protein C inhibitor in purified mixtures and in plasma.
España F; Estelles A; Griffin JH; Aznar J
Thromb Haemost; 1991 Jan; 65(1):46-51. PubMed ID: 1850876
[TBL] [Abstract][Full Text] [Related]
35. Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo.
Geiger M; Huber K; Wojta J; Stingl L; Espana F; Griffin JH; Binder BR
Blood; 1989 Aug; 74(2):722-8. PubMed ID: 2752144
[TBL] [Abstract][Full Text] [Related]
36. ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1).
Grebenschikov N; Sweep F; Geurts A; Andreasen P; De Witte H; Schousboe S; Heuvel J; Benraad T
Int J Cancer; 1999 May; 81(4):598-606. PubMed ID: 10225451
[TBL] [Abstract][Full Text] [Related]
37. Complexes of tissue kallikrein with protein C inhibitor in human semen and urine.
España F; Fink E; Sanchez-Cuenca J; Gilabert J; Estellés A; Witzgall K
Eur J Biochem; 1995 Dec; 234(2):641-9. PubMed ID: 8536714
[TBL] [Abstract][Full Text] [Related]
38. Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma.
Wakita T; Hayashi T; Nishioka J; Tamaru H; Akita N; Asanuma K; Kamada H; Gabazza EC; Ido M; Kawamura J; Suzuki K
Int J Cancer; 2004 Feb; 108(4):516-23. PubMed ID: 14696115
[TBL] [Abstract][Full Text] [Related]
39. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Biochemical and multicenter validation of a two site immunosorbent assay.
Rånby M; Nguyen G; Scarabin PY; Samama M
Thromb Haemost; 1989 Jun; 61(3):409-14. PubMed ID: 2508254
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of plasminogen activators attenuates the death of differentiated retinal ganglion cells and stabilizes their neurite network in vitro.
Harvey R; Chintala SK
Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1884-91. PubMed ID: 17389524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]